all

Nov. 10, 2018

NLA among 12 organizations to co-author, endorse key document for reducing risk of atherosclerotic cardiovascular disease

Oct. 25, 2018

Amgen announced on Wednesday, Oct. 24 it is making evolocumab available at a reduced list price in an effort to improve affordability and access for patients.

The announcement represents positive news for patients at risk for cardiovascular events.

Key outcomes from Amgen’s FOURIER trial, revealed in March 2017, revealed evolocumab significantly reduced the risk of cardiovascular events and were supported by long-term safety data.

Watch this special webinar hosted by the American Heart Association (AHA) and the Pacific Lipid Association (PLA) on how to equip healthcare providers and patients with proven tools to achieve better cholesterol management.